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Evaluations and Pricing 
Paul C Langley, PhD 
College of Pharmacy, University of Minnesota, Minneapolis, MN  
 
ABSTRACT 
Next generation sequencing (NGS) has the potential to disrupt not only the accepted process of drug development but also the 
hurdles a drug manufacturer would be expected to face in securing formulary approval and a possible premium price for the new 
compound. The purpose of this commentary is to consider the role of NGS in this process, one which is characterized as a process of 
creative destruction, where adoption of NGS in personalized medicine sets in train a mechanism of incessant product and process 
review. A mechanism driven by continuing modifications and extensions to NGS platforms as our understanding of the role of 
mutations and mutation load in therapy choice expands. At the same time this mechanism has significant implications for the 
continued revision of treatment guidelines and their adoption of NGS as integral parts of the treatment pathway. There are, however, 
a number of unresolved issues which have to be addressed. These include the choice of NGS platform, barriers to integrating evidence 
to support NGS-based therapy choices in treatment guidelines, the implications of NGS for drug development and the modification or 
rejection of current trial structures, the integration of comorbid disease states and the standards that formulary committees should 
adopt to evaluate NGS claims. The overarching theme, however, is the need to invest in a robust and credible evidence base. While 
we are a long way from achieving this, the focus must be on putting claims for therapy choice forward that are credible, evaluable 
and replicable.    
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INTRODUCTION 
Next generation sequencing (NGS) has the potential to 
disrupt not only the accepted process of drug development 
but also the hurdles a drug manufacturer would be expected 
to face in securing formulary approval and a possible 
premium price for a new compound. NGS is not simply ‘one 
new test’. The implications of the adoption of NGS testing go 
much further. NGS testing may be usefully considered as one 
supporting Schumpterian ‘creative destruction’ in the 
development and adoption of new therapies 1. Adoption of 
NGS in personalized medicine sets in train a mechanism of 
incessant product and process review. A mechanism driven 
by continuing modifications and extensions to NGS platforms 
as our understanding of the role of mutations and mutation 
load in therapy choice expands. 
 
The purpose of this commentary is to consider: (i) the role 
and choice of NGS platform; (ii) possible barriers to  
integrating evidence to support NGS-based therapy choices in 
treatment guidelines; (iii) the implications of NGS for drug  
development; (iv) the modification or rejection of current 
trial structures; (iv) the integration of comorbid disease 
states; and (v) the standards that formulary committees  
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should adopt to evaluate NGS claims. The overarching theme, 
is the importance of developing a believable evidence base to  
support NGS-sourced claims for therapy interventions.  
 
Unfortunately, all NGS platforms are not created equal. The 
various platforms have the potential not only to yield 
different profiles of mutation clusters and mutation load 
within disease states but also to overlook mutations due to 
restrictions on the genes that are captured as inputs.  
 
A recent draft guidance issued by the Food and Drug 
Administration (FDA) argues for public access to a database of 
human genetic variants ‘that aggregates and curates reports 
of human phenotype-genotype relationships to a disease or 
condition’ both with documentation to support linkages and 
assertions regarding specific genotype-phenotype 
correlations 2. Access to a genetic variant data base could 
support claims for the clinical validity of an NGS test (and 
support comparative test assessments) and alleviate concerns 
for the test’s safety and validity.   
 
The principal concern of the FDA is with valid scientific 
evidence. However, it is not clear from the draft guidance 
whether the FDA sees its remit as limited to the evaluation of 
clinical validity or whether the concern for the clinical 
outcomes from the application of the NGS links to therapies 
in target populations is the ultimate target. This would raise 
the evidence bar significantly higher and, given the elapsed 
time to undertake trial-based clinical assessments (or even 
protocol driven observational studies) would put a brake on 
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the adoption of NGS-based precision medicine interventions. 
A further question, inevitably, is whether access to such a 
database (or databases) would eliminate the incentive for the 
commercial development of NGS platforms? 
 
CHOICE OF NGS PLATFORM 
NGS platform tests vary in their scope in the number of genes 
that are reviewed. As the number of mutations, their clusters 
and overall mutation load will be a function of the test 
platform, apart from the tests analytical and clinical validity, 
care has to be taken by manufacturers, formulary committees 
and treatment guideline panels in selecting the test that is 
adopted as their ‘gold standard’. In a recent commentary the 
issue of test standards and the criteria that should be applied 
in both choosing a test and assessing the merits of competing 
tests was examined 3. The commentary pointed to the 
absence of NGS test standards other than those in place for 
analytical and clinical validity by the Centers for Medicare and 
Medicaid Services (CMS) and the Food and Drug 
Administration (FDA).  As noted above, there is uncertainty as 
to how the FDA might evaluate and approve NGS tests if, as 
expected, they are considered class 3 medical devices.  
 
In any event, the issue facing manufacturers, formulary 
committees and guideline developers such as the National 
Cancer Center Network (NCCN) in the absence of 
recommendations for platform NGS tests is the choice of a 
test to link mutation profiles to therapy options. Competing 
tests may, if there is no public access variant database, yield 
different frequencies of mutations and estimates of mutation 
load in the same target tumors. This places an additional 
burden on health system decision makers and those 
reviewing and updating treatment guidelines if, as expected, 
there is a push towards integration of NGS within treatment 
guidelines. If the FDA brings in standards, then guidelines 
may refer simply to any FDA approved platform. One 
implication is that if a manufacturer presents a case for a 
therapy linked to specific mutations in a target population 
based on a basket trial design covering multiple therapy 
options, then the NGS test supporting the basket trial should 
be a test that is endorsed by the formulary committee. If the 
preferred formulary test generates a distribution of mutation 
clusters at variance from those generated by the basket trial, 
then there is no basis for accepting trial based claims. This 
becomes more worrisome if, in presenting a modeled case for 
an intervention, the model brings together data elements to 
populate a trial pathway structure that rest upon disparate 
trials that rely on a range of competing NGS platforms. 
 
In the last resort, of course, if guidelines are in place that 
require claims to be evaluated and replicated in a target 
population, then the issue is resolved if the formulary 
committee insist on a specific NGS platform to support all 
randomized clinical trial (RCT) and observational study 
protocols. To date, however, only one US proposed guideline, 
developed at the University of Minnesota, has recommended 
that any submission for formulary approval and pricing for a 
therapy should be supported by a claims assessment protocol 
4.  Such a protocol, where NGS-based therapy claims are the 
focus of an assessment would be funded by the manufacturer 
hoping to bring a new compound into therapy, as a substitute 
for or a complement to existing compounds.  Given the sheer 
complexity of attempting to model NGS driven interventions 
in late stage cancer, to give the most obvious area for NGS 
interventions, a premium must be placed on the need to 
establish a coherent and believable evidence base. One 
avenue would be to endorse standards for the modeling of 
NGS interventions, with the focus not only on developing 
credible, evaluable and replicable claims but ensuring 
documented feedback to decision makers. Submission 
protocols for claims assessment would be an integral part of 
this process.  
 
TREATMENT GUIDELINES 
At the present time, treatment guidelines are silent on 
references to NGS assessments by disease stage. The 
melanoma guidelines, for example, recommend ‘mutational 
analysis’ as a workup at stage III of disease progression for 
patients being considered for either routine treatment or for 
clinical trials while at the metastatic stage IV it is 
recommended if a patient is being considered for targeted 
therapy or if required for eligibility in a clinical trial 5. There is 
no explicit recommendation for NGS or how to interpret the 
results of an assessment for therapy choice. 
 
If treatment guidelines are to inform clinical decisions, far 
more needs to be done to make explicit the contribution and 
application of NGS platforms to guide therapy choice for 
individual patients. Far more also needs to be done to 
provide a robust evidence base. A feature of many treatment 
guidelines, and melanoma is no exception, is the relative 
paucity of evidence to support pharmacological treatment 
decisions, in particular in late stage disease. In the melanoma 
guidelines, for example, evidence to support pharmacological 
interventions in late stage III and IV disease is typically 
classified as low level 2B: without uniform consensus of the 
assessment panel (below the NCCN default consensus 
category, still low level, of 2A). In advanced Stage IV 
metastatic therapy options are limited (i) to systemic non-
molecular targeted therapy with nivolumab, pembrolixumab 
or ipilumab, (ii) single mutation targeted monotherapy with 
vemurafenib or imtinib for patients with BRAF mutant tumors 
and BRAF wild type tumors; (iii) combination targeted 
BRAF/MEK inhibitors with trametinib or cobimetinib 
(respectively targeting MEK1 and MEK2 signaling molecules 
or (iv) imatinib for c-KIT mutations. In all cases the response 
was considered acceptable, ranging as high as 60% for 
nivolumab, with others in the range 20% to 40%. The 
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drawbacks are that only half of patients with cutaneous 
metastatic melanoma harbor a BRAF mutation and of these 
some 50% relapse within six months. While the combination 
BRAF/MEK therapy improved response, time to relapse was 
little different from BRAF monotherapy. To illustrate the 
limitations of non-targeted monotherapy, the NCCN 
guidelines note that trials for unselected patients with 
imatinib failed to yield a therapeutic response.  
 
The implications of experience with targeted monotherapy in 
metastatic melanoma should come as no surprise. While 
evidence for overall survival is lacking, the favorable response 
rates have to be set alongside a median time to relapse of six 
months. At the same time, little attention is given to the role 
of toxicity and adverse events in discontinuation. The promise 
of NGS platforms is that linked to therapy options they may 
not only provide recommendations for therapy links to 
mutation clusters, but there may be a choice between 
therapy options that are projected to yield a more benign 
side effect profile. 
 
DRUG DEVELOPMENT 
From the perspective of drug development, the adoption of 
NGS by formulary committees and health care systems raises 
three concerns:  
(i) that the target population is essentially a ‘niche’ 
population which, unless a premium price can be 
guaranteed argues against drug development;   
(ii) that by the time the product, with an expectation of 
a premium price, reaches the formulary submission 
and price negotiation stage, the application of NGS 
by the health system may have identified low cost 
compounds to support interventions in particular 
therapy pathways which further limit the market 
(and may even replace the new entrant), weakening 
the bargaining position for a premium price; and  
(iii) that modeled cost-outcomes claims will have to be 
not only credible, evaluable and replicable but 
presented in a framework that recognizes the 
frequency of mutation clusters, mutation load and 
the multiplicity of treatment pathways linked to 
specific mutation clusters. 
The standard model of drug development from preclinical to 
a possible post-market entry phase is well established. With a 
growing appreciation of the power of NGS testing and the 
hypotheses formulated by the matching of single or multiple 
drug combination to a particular class or group of mutations, 
this process is expected to be modified substantially. NGS can 
be applied at any stage of drug development as well as 
supporting phase 4 effectiveness studies that may be 
required by formulary committees to establish the credibility, 
evaluation and replication of NGS-modulated drug 
assessments in target populations. 
 
The role of NGS testing in drug development is essential if we 
are potentially to avoid the ‘wastage’ associated with the 
standard model (historically non-genomic for the large part) 
of drug development. This applies equally to the more recent 
attention given to evaluating drugs in terms of a single 
molecular marker. As noted above, combining targeted 
therapy with immunotherapy in BRAF-mutant melanoma may 
enhance the relatively high initial response rates as well as 
enhancing survival by substantially increasing median time to 
relapse 6. NGS offers the possibility of a full genomic screen 
with the identification and the matching of multiple mutation 
combinations, mutation load, to corresponding monotherapy, 
or more likely, combination therapy treatment pathways. 
Again, in the case of melanoma, an NGS screen of hotspot 
regions in 46 genes not only identified mutations in 43 of 
those genes but one-third of the melanomas had > 1 
mutation detected, with the number and type of mutations 
per tumor linked to melanoma subtype 7  A new compound, 
therefore, has to face comparison against, not just a notional 
standard of care (or even placebo) but has to be assessed in 
the context of multiple treatment pathways by stage of 
disease in tumor types. It also has to take account of changing 
tumor expression and the possibility that a pathway may 
become redundant as the tumor evolves. It must also 
recognize that there may be no evidence to match mutations 
to therapy options and patients may have to be assigned to 
palliative care. Indeed, the contribution of a new compound 
maybe more of a transitory phenomenon as further NGS 
profiling maps changing mutation expression and suggests 
modification or abandonment of prior recommended 
pathways, bring in a range of existing and new compounds. 
Manufacturers may have to face the reality that investment 
in a new compound, or the acquisition of a new compound at 
late development, may simply be bringing to market a 
compound that is put alongside hundreds of others in the 
library of compounds for matching to mutation profiles.  
 
Even at phase 1of clinical development, the dose ranging 
evaluation will have to be in terms of the genetically defined 
target population within a stage of disease specific tumor 
type. If done properly, the NGS assessment in a notional 
target population (defined by stage of disease and response 
to previous therapies) will yield a distribution of mutation 
clusters and estimates of mutation load which can be linked 
to clinical outcomes 8 9.  This can be extensive and may 
involve dozens of clusters. Each cluster will define a target 
population with the recommended matched therapy 
involving either a single compound (the one being developed) 
or a combination of therapies that include the new 
compound. This is the context for future drug development 
or, more likely perhaps, a decision to abandon development. 
Put simply, the target mutation cluster ‘niche’ may simple be 
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too ‘small’ to justify drug development and the possible 
obstacles to achieving a premium or rent-seeking price.  
 
At the same time, care has to be taken in establishing the 
assessment framework. With multiple mutation clusters and 
complementary treatment pathways, there is the possibility 
that the performance of drugs in a given pathway will be 
impacted by the choice of competing pathways with the 
possibility of drug-drug interactions modifying the pathways 
defined within the assessment platform. Single molecule 
claims may, therefore, be misleading as a basis for choosing 
therapy options. At least, looking ahead to the standards a 
formulary committee is likely to set for claims assessment, 
failure to consider possible interactions, in clinical designs at 
phases 1, 2 and 3 of drug development, may qualify 
outcomes claims. Once again, the question is one of 
establishing a robust and coherent evidence base. Integrating 
NGS sequencing in drug development is only the first step. 
Manufacturers have to convince reimbursers that their 
product adds value in its contribution to therapy specific 
pathways. 
 
COMORBIDITIES 
Older patients who are seen as a major target group for NGS 
sequencing in late stage cancers will also present with a 
number of comorbidities.  The question then becomes one of 
whether or not the patient will potentially benefit from an 
NGS evaluation that also captures the mutations present in 
the comorbid disease states?  In diabetes, for example, which 
is one of the more common comorbidities in older 
populations, a patient may also be receiving tailored therapy 
based on NGS profiles 10. This could also be directed towards 
issues such as the presence of pain as a side effect of choices 
in specific therapy pathways. NGS profiling could be an 
important adjunct in the management of pain both as a side 
effect and as a disease in its own right.11. A patient may have 
tailored NGS-based therapies for a number of comorbid 
disease states, with little guidance from the NGS profile for 
possible drug-to-drug interactions or more complex 
interactions at the molecular level. 
 
While it might be argued that neglect of complementary 
treatment pathways is no different from comorbidity 
exclusion criteria in classical trial design, the case of tumor 
suppression is more complex. The presence of comorbidities 
not only makes the personalized medicine package more 
complex at the patient level (with implications for possibly 
closer monitoring of patients) but also raises questions as to 
the appropriate design of basket trials. The options open and 
the potential costs of targeting multiple pathways within trial 
design may also lead to greater emphasis on post-marketing 
approval observational studies to re-assess trial-based and 
modeled claims.  
 
FORMULARY COMMITTEE REQUIREMENTS 
Standards in place for formulary submissions by groups in the 
US such as the Academy of Managed Care Pharmacy (AMCP) 
and the Institute for Clinical Effectiveness Research (ICER) are 
not designed to accommodate NGS-driven clinical and cost-
outcomes claims 12 13. Neither the AMCP guideline focus nor 
the ICER attempt to replicate the NICE reference case meet 
the standards that modeled claims should be credible, 
evaluable and replicable (e.g., lifetime cost-per-quality 
adjusted life year [QALY] claims). To date, no attention has 
been given to the standards for basket trial designs and the 
modeling of specific claims based on an NGS platform. From 
the perspective of a formulary committee, there is no 
appreciation of the challenge posed by the need to evaluate 
claims for a new compound in the context of an NGS-driven 
mutation profile linked to multiple intervention pathways.  
 
As an example of this single-molecule modeling that puts to 
one side the contribution of NGS to therapy choice and the 
positioning of new compounds in a basket-trial approach to 
drug development and claims, consider the ICER report on 
treatment options for non-small cell lung cancer (NSCLC) 14. 
The primary aim of the analysis was to estimate the cost-
effectiveness of treating NSCLC patients with first-line 
tyrosine kinase inhibitors (TKIs) versus a chemotherapy 
doublet (cisplatin+pemetrexed) for epidermal growth factor 
receptor (EGFR) patients, and second-line treatment with 
programmed death 1 receptor (PD-1) immunotherapy versus 
docetaxel among patients who have progressed on a first-line 
chemotherapy doublet. Comparative clinical effectiveness 
was based on evidence from not the EGFR mutation but on 
EGFR patients without any driver mutation. Evidence for PD-1 
immunotherapy as first or second line treatment was also 
limited. The systematic reviews of available evidence were 
unable to distinguish between the TKIs in overall survival and 
quality of life, although all three TKI compounds (afatinib, 
erlitinib and gefitinib) were superior to chemotherapy. 
Similarly, with PD-1, different assays and cut off points to 
measure programmed death ligand 1, the evidence was 
inadequate to compare PD-1 therapies for any outcome.  
 
Nevertheless, building on this limited evidence base, ICER 
proceeded to undertake a comparative value analysis 
focusing on costs, outcomes and cost-effectiveness. Evidence 
for comparative cost-effectiveness was constructed in the 
framework of a partition survival model for two FDA-labeled 
indications: (i) first line TKI treatment strategies; and (ii) 
second-line PD-1 treatment strategies. Three health states 
were assumed for the model: (i) progression free; (ii) 
progression; and (ii) death. Mean time spent in each state, 
quality adjusted time, and direct medical costs were 
estimated and summed to provide estimates of life 
expectancy, quality adjusted life expectancy, and total costs. 
A cycle length of one week was applied to reflect the dosing 
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schedules for drug regimens. The model took a lifetime 
horizon, modeling patients from treatment initiation until 
death.  
 
Outcomes from the model were: (i) quality adjusted life years 
(discounted); (ii) life years (discounted); (ii) mean time in the 
progression-free and post-progression health states 
(discounted); (iii) pre-progression, post-progression, and total 
costs (discounted); and (iv) Incremental cost-effectiveness 
ratios for each intervention versus the standard comparator 
(cisplatin+pemetrexed or docetaxel), in pair wise 
comparisons. None of these outcomes were presented in an 
evaluable form. Nor was any protocol suggested to assess the 
various claims although the survival times were relatively 
short (under 30 months). As noted in previous commentaries, 
non-evaluable modeled claims do not meet the standards of 
normal science and should be rejected. Indeed, in the 
absence of a prospective study which stipulates the collection 
of quality of life data (from, presumably, a ‘gold-standard’ 
generic measure) claims for cost-per-QALY (even if non-
discounted) are impossible to verify. This is unfortunate as 
projected (non-evaluable) cost-per-QALY claims are central to 
ICER pronouncements on whether WAC pricing is ‘cost-
effective’.  
 
The absence of NGS-driven basket trials for the various 
compounds in an attempt to link the various compounds to 
therapy pathways is a major, if not a fatal flaw, in attempting 
to make a case to a formulary committee. Much of the blame 
must attach to the manufacturers choice of trial design and 
the limited evidence base available for any comprehensive 
comparative analysis. For a formulary committee that adopts 
an NGS-driven assessment program the claims presented by 
ICER are of little interest. Although the ICER 
recommendations for value-based price benchmarks, with 
their recommendations for wholesale acquisition cost (WAC) 
discounts to achieve the notional $100,000 per QALY gained 
threshold have, no doubt, attracted the ire of the respective 
manufacturers, the more substantive criticism is that in the 
context of treatment guidelines driven by NGS, such a partial 
exercise is really a waste of time. 
 
The ICER approach faces two major objections: (i) the model 
framework does not meet the standards of normal science in 
generating credible, evaluable and replicable hypotheses and 
(ii) the modeling framework is focused on a single molecule. 
In the context of a commitment by a health system to NGS as 
the basis for the choice comparative assessments of therapy 
options targeted to the distribution of mutations and 
mutation load, the single molecule approach is not only 
redundant but potentially misleading for formulary 
acceptance, therapy pathway choice and pricing. 
 
Formulary committees are unlikely to find single pathway 
models linking a specific mutation to the manufacturer’s 
target therapy convincing. If a modeled case is made for the 
therapy, then the manufacturer will, by analogy to the 
inclusion and exclusion criteria of the classical phase 3 trials, 
have to justify which of the potentially large number of 
treatment pathways have been selected for inclusion or 
exclusion. This may be a hazardous exercise given the 
potential for interactions between the therapy choices 
defining individual pathways. One possible criterion would be 
the most frequently expressed mutation complexes so the 
model may focus on integrating the new compound in a 
model structure that traces out five or six therapy paths. 
These paths would have common endpoints of, say, median 
survival or median time to relapse in a late stage metastatic 
intervention, together with possible metrics of satisfaction, 
pain and quality of life. A clinical and cost-effectiveness 
model might then be constructed to generate credible claims.  
The model would be designed to generate claims for each 
pathway as well as across all pathways for the sub-targeted 
population that the mutation choice represents. 
 
CONCLUSIONS 
The adoption of NGS to drive treatment guidelines and 
formulary decisions implies a need for a major rethink of the 
process of drug discovery and the evidence base for therapy 
clams. Moving away from a ‘one size fits all’ paradigm in drug 
development where the target populations are defined by 
clinical characteristics rather than genomic profiling is likely 
to disrupt the traditional process of drug discovery. Rather 
than being satisfied with a relatively low response rate, high 
rates of relapse and limited survival prospects, NGS 
assessments promise through personalized medicine a more 
clinically rigorous and targeted approach to therapy choice. 
At the same time, single molecule targeting of therapies is 
also likely to be rejected.  
 
This process of restructuring in drug discovery and treatment 
choice, Schumpterian ‘creative destruction’ or ‘industrial 
mutation’, holds the promise of greater productivity in drug 
discovery and treatment. As our understanding of the 
molecular basis of disease improves, NGS platforms will 
evolve. This mechanism of incessant product and process 
innovation will not only face manufacturers with the 
challenge of justifying investments in new compounds but 
will also, hopefully, encourage practitioners in health 
technology assessment to abandon their commitment to 
modeling non-evaluable artificial cost and outcomes 
scenarios; an appreciation of the standards of normal science 
through fashioning claims that are credible, evaluable and 
replicable. It is only in this context that the benefits of NGS 
can be realized.  
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